Solutions and future perspectives -potential solutions to the current problem: Coated balloon

EuroIntervention

Volumn 4, Issue , 2008, Pages C63-C66

  Scheller, Bruno ^a   Speck, Ulrich ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; IOPROMIDE; PACLITAXEL; RAPAMYCIN;

ANTIPROLIFERATIVE ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; CORONARY ANGIOGRAPHY; CORONARY STENTING; DRUG ABSORPTION; DRUG SOLUBILITY; EPITHELIZATION; EVIDENCE BASED MEDICINE; HUMAN; IN-STENT RESTENOSIS; MATERIAL COATING; OUTCOME ASSESSMENT; RESTENOSIS; SUSTAINED DRUG RELEASE; CELL DIVISION; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG ELUTING STENT; EQUIPMENT DESIGN; INTIMA; MORTALITY; MULTICENTER STUDY; PATHOLOGY;

CELL DIVISION; CLINICAL TRIALS AS TOPIC; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; HUMANS; MULTICENTER STUDIES AS TOPIC; TUNICA INTIMA;

EID: 63149152187     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation, 2001;104: 600-5.
2. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 1997;96: 636-645.
3. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: Biological effects and efficacy in vivo. J Am Coll Cardiol, 2000;35: 1969-96.
4. Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Böhm M, Stoll HP: Contrast Media as a Carrier for Local Drug Delivery: Successful Inhibition of Neointimal Proliferation in the Porcine Coronary Stent Model. Eur Heart J 2003; 24: 1462-7.
5. Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol; 2003;42: 1415-20.
6. Iofina E, Langenberg R, Blindt R, Kuhl H, Kelm M, Hoffmann R. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Am J Cardiol, 2006;98: 1022-7.
7. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol, 2006;48: 193-202.
8. van der Giessen WJ, Lincoff AM, Schwartz RS et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation, 1996;94: 1690-7.
9. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? Circulation, 9999;109: 701-5.
10. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003;349: 1315-23.
11. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating -A novel method for prevention and therapy of restenosis. Circulation, 2004;110: 810-4.
12. Scheller B, Speck U, Böhm M. Prevention of Restenosis -is Angioplasty the Answer? Heart 2007; 93: 539-41.
13. Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo H. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol, 2006;58: 665-72.
14. Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Böhm M, Hamm B. Restenosis Inhibition by Non-stent-based Local Drug Delivery: Comparison of Efficacy to a Drug Eluting Stent in the Porcine Coronary Overstretch Model. Radiology, 2006;240;411-8.
15. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Küttner A, Schröder S, Haase KK, Karsch KR. Visualization and comparison of drug effects after local paclitaxel delivery with different catheter types. Basic Res Cardiol, 1999;94: 454-63.
16. Kipshidze N, Dangas G Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P. Role of endothelium in modulating neointimal formation. Vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol, 2004;44: 733-9.
17. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res, 2006;98: E20-5.
18. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Treatment of In-stent Restenosis with a Paclitaxelcoated Balloon Catheter. New Engl J Med, 2006;355: 2113-24.
19. Scheller B. PACCOCATH ISR 1 and 2: A Prospective, Randomized Trial of a Paclitaxel-Eluting Balloon in In-Stent Restenosis: 2-Year Results. Transcatheter Cardiovascular Therapeutics TCT, October 24, 2007; Washington, DC, USA.
20. Tepe G, Zeller T, Albrecht T, Speck U. Local Taxan with short time contact for reduction of restenosis in distal arteries. 12 -months data. THUNDER Trial. Transcatheter Cardiovascular Therapeutics TCT, October 23, 2007; Washington, DC, USA.
21. Unverdorben M. The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease: PEPCAD I-SVD. PEPCAD II-ISR. Transcatheter Cardiovascular Therapeutics TCT, October 24, 2007; Washington, DC, USA.